ArticleClinical cancer research : an official journal of the American Association for Cancer Research2017
Immunotherapy for Breast Cancer: What Are We Missing?
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 141 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
141 citing papers in PubMed, 2 syntheses or guidelines pooled it, 236 citations in OpenAlex.
- Knowledge mapping of global trends in DNA damage repair-related breast cancer research: a bibliometric study.Frontiers in oncology · 2025Pooled it
- Pooled it
- Paclitaxel plus Eftilagimod Alpha, a Soluble LAG-3 Protein, in Metastatic, HR+ Breast Cancer: Results from AIPAC, a Randomized, Placebo Controlled Phase IIb Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Trial
- Tumour-Infiltrating Inflammatory Cells in Early Breast Cancer: An Underrated Prognostic and Predictive Factor?International journal of molecular sciences · 2020Trial
- Glutathione-depleting self-immolative nanoparticles boost cuproptosis-driven metalloimmunotherapy for triple-negative breast cancer.Journal of nanobiotechnology · 2026Article
- Tumor sialylation regulates G-CSF stability and promotes neutrophil-mediated immunosuppression in breast cancer.Nature communications · 2026Article
- Cholesterol efflux protein, ABCA1, supports anticancer functions of myeloid immune cells.Science advances · 2026Article
- Exploring Cutting-Edge Strategies for the Management of Triple-Negative Breast Cancer Through Drug Repurposing.Current topics in medicinal chemistry · 2026Review
- PLA2G16-Mediated Tetracosatetraenoic Acid Rewires Fatty Acid Oxidation to Impair CD8Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Single-Cell Transcriptomics Reveals the Potential Role of GZMK+ CD8+ T Cells in Cell Senescence of Triple-Negative Breast Cancer.International journal of genomics · 2026Article
- Tissue-resident memory T cells reshapeFrontiers in immunology · 2026Review
- Induced Electric Fields Inhibit Breast Cancer Growth and Metastasis and Modulate the Immune Tumor Microenvironment.Breast cancer (Dove Medical Press) · 2026Article
- Interaction between the breast tumor microenvironment and gut microbiome.Gut microbes · 2025Review
- Nano-Based Vaccine Delivery Systems: Innovative Therapeutics Against Cancer and Neurological Disorders.International journal of molecular sciences · 2025Review
- Recent advances in immunotherapy for breast cancer.Discover oncology · 2025Review
- LARS2 DNA methylation predicts the prognosis in colon cancer.Scientific reports · 2025Article
- Immunotherapy in breast cancer: current landscape and emerging trends.Experimental hematology & oncology · 2025Review
- Effects of pregnancy on breast cancer immunology: immune biomarker and TIL quantification.NPJ breast cancer · 2025Article
- CCNE2 promotes cisplatin resistance and affects prognosis of head and neck squamous cell carcinoma by targeting MNAT1.Scientific reports · 2025Article
- Inhibiting glycolysis facilitated checkpoint blockade therapy for triple-negative breast cancer.Discover oncology · 2025Article
81 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
The recent demonstration of modest single-agent activity of programmed death-ligand 1 (PD-L1) and programmed death receptor-1 (PD-1) antibodies in patients with breast cancer has generated hope that breast cancer can be made amenable to immunotherapy. Depending on the subtype of breast cancer, it is now clear in both primary and metastatic disease that the extent of tumor-infiltrating T cells is not only prognostic for survival but predictive of response to nonimmune, standard therapies. Despite these findings, immune cytolytic activity in spontaneous breast tumors, the burden of nonsynonymous tumor mutations, and the predicted load of neoepitopes-factors linked to response to checkpoint blockade in other malignancies-are all relatively modest in breast cancer compared with melanoma or lung cancer. Thus, in breast cancer, combinations of immune agents with nonredundant mechanisms of action are high-priority strategies. For most breast cancers that exhibit relatively modest T-cell infiltration, major challenges include immune suppression in the tumor microenvironment as well as failed or suboptimal T-cell priming. Agents that trigger
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.